Alliqua Inc. (NASDAQ:ALQA)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report released on Tuesday.

Separately, Zacks Investment Research upgraded Alliqua from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research report on Thursday, August 11th. Six research analysts have rated the stock with a buy rating, Alliqua has an average rating of “Buy” and a consensus price target of $2.42.

Analyst Recommendations for Alliqua (NASDAQ:ALQA)

Alliqua (NASDAQ:ALQA) opened at 0.58 on Tuesday. The stock’s market capitalization is $17.21 million. The stock’s 50 day moving average is $0.76 and its 200-day moving average is $0.99. Alliqua has a 52 week low of $0.57 and a 52 week high of $2.90.

Alliqua (NASDAQ:ALQA) last released its earnings results on Tuesday, August 9th. The company reported $0.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.32. The company earned $5.50 million during the quarter, compared to the consensus estimate of $5.38 million. Alliqua had a negative return on equity of 52.26% and a negative net margin of 81.72%. Equities research analysts forecast that Alliqua will post ($0.74) EPS for the current year.

A number of hedge funds have recently made changes to their positions in ALQA. Suffolk Capital Management LLC increased its stake in shares of Alliqua by 4.8% in the third quarter. Suffolk Capital Management LLC now owns 1,264,101 shares of the company’s stock valued at $1,011,000 after buying an additional 57,974 shares during the last quarter. US Bancorp DE increased its stake in shares of Alliqua by 29.8% in the second quarter. US Bancorp DE now owns 181,732 shares of the company’s stock valued at $204,000 after buying an additional 41,732 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Alliqua by 1.1% in the second quarter. Vanguard Group Inc. now owns 524,296 shares of the company’s stock valued at $587,000 after buying an additional 5,780 shares during the last quarter. Hedge funds and other institutional investors own 29.90% of the company’s stock.

Alliqua Company Profile

Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.

5 Day Chart for NASDAQ:ALQA

Receive News & Stock Ratings for Alliqua Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Inc. and related stocks with our FREE daily email newsletter.